ObjectiveTo detect the levels of serum solute carrier family 7 member 11 (SLC7A11) and serum fibroblast growth factor 23 (FGF23) in patients with atrial fibrillation (AF) and sinus rhythm, and analyze the correlation between them and AF and their clinical significance.
MethodsA total of 120 AF patients who were hospitalized were selected as observation group. According to relevant guidelines, they were divided into paroxysmal AF group (70 cases) and non-paroxysmal AF group (50 cases). In the control group, 96 healthy patients with sinus rhythm were selected. The concentrations of SLC7A11 and FGF23 in serum were measured by enzyme-linked immunosorbent assay (ELISA). The clinical data and serological indexes of the three groups were compared, and the correlation between serum SLC7A11 and FGF23 levels and left atrial diameter (LAD), left ventricular diastolic diameter (LVD), left ventricular ejection fraction (LVEF) and left ventricular shortening fraction (FS) in echocardiography was analyzed by Pearson correlation analysis. Multivariate logistic regression was used to analyze the factors related to the occurrence and persistence of AF in patients with AF.
ResultsCompared with control group, serum SLC7A11 was decreased in paroxysmal AF group and in non-paroxysmal AF group (P < 0.01), and SLC7A11 in non-paroxysmal AF group was lower than that of paroxysmal AF group (P < 0.01);serum FGF23 was increased in paroxysmal AF group and in non-paroxysmal AF group (P < 0.01), and FGF23 in non-paroxysmal AF group was higher than that of paroxysmal AF group (P < 0.01). Pearson correlation analysis showed that LAD was negatively correlated with serum SLC7A11 (r=0.534, P < 0.01), and positively correlated with serum FGF23 (r=0.532, P < 0.01). Multiple logistic regression analysis results showed that SLC7A11 was an independent protective factor for AF (OR=0.231, P < 0.01), while FGF23 was an independent risk factor (OR=1.097, P < 0.01).
ConclusionsSLC7A11 and FGF23 may be associated with the occurence and progression of AF.
DownLoad: